이 애플리케이션의 일부 콘텐츠는 현재 사용할 수 없습니다.
이 상황이 계속되면 다음 주소로 문의하십시오피드백 및 연락
1. (WO2018060878) EEG MICROSTATES FOR CONTROLLING NEUROLOGICAL TREATMENT
유의사항: 이 문서는 자동 광학문자판독장치(OCR)로 처리된 텍스트입니다. 법률상의 용도로 사용하고자 하는 경우 PDF 버전을 사용하십시오

WHAT IS CLAIMED IS:

1. A method for evaluating a treatment for a brain condition, comprising: extracting one or more microstate parameter values from at least one EEG signal that was measured after the treatment; and

evaluating at least one parameter of the treatment based on the one or more microstate parameter values.

2. The method of claim 1, wherein the microstate parameter values represent at least one brain activity state and/or at least one cognitive state.

3. The method of claims 1 or 2, further comprising determining if the one or more microstate parameters values are in a desired range of values and/or in a desired relation from at least one indication or value.

4. The method of claim 3, wherein the determining further comprises: comparing the one or more microstates parameters values to at least one desired value and/or an indication of a desired value;

wherein the desired value and/or the indication of a desired value is in the desired range of values.

5. The method of claims 3 or 4, wherein the extracting further comprises extracting one or more microstate parameters values from at least one EEG signal that was measured before the treatment.

6. The method of claim 5, wherein the determining further comprises comparing one or more microstate parameters values of an EEG signal that was measured after the treatment, to one or more microstate parameters values of an EEG signal that was measured before the treatment, and determining a change in at least one of the microstate parameters values.

7. The method of claim 6, wherein the determining further comprises determining if the change in at least one of the microstate parameters values is a desired change.

8. The method of any of the previous claims, wherein the microstate parameters values represent brain activity related to at least one cognitive domain selected from a list comprising: memory, language, visuospatial ability, attention, abstract thinking, planning and/or executive function.

9. The method of any one of the previous claims, further comprising: modifying at least one parameter of the treatment if the one or more microstate parameters values is not a desired value.

10. The method of any one of the previous claims, wherein the microstate parameters comprise resting state networks or resting state microstate parameters, and wherein the EEG signal is measured when an individual is not actively engaged in sensory and/or cognitive processing.

11. The method of any of the previous claims, wherein the brain condition comprises Mild cognitive impairment (MCI), dementia or Attention Deficit Hyperactivity Disorder or Attention Deficit Disorder or Depression.

12. The method of claim 11, wherein the dementia comprises Alzheimer's disease (AD), Vascular dementia, Dementia with Lewy Bodies (DLB), Mixed dementia, Parkinson's disease related dementia, Frontotemporal dementia, Creutzfeldt-Jakob disease (CJD), Normal pressure hydrocephalus related dementia and/or Huntington's disease related dementia.

13. The method of any of the previous claims, wherein the evaluating further comprises evaluating the efficacy and/or the efficiency of the treatment.

14. The method of claim 13, further comprising:

delivering a TMS by at least one magnetic coil attached to the scalp, before the extracting.

15. The method of claim 14, further comprising:

modifying at least one parameter of the TMS based on the efficacy.

16. The method of claim 15, wherein the at least one parameter comprises TMS pulse frequency, magnetic field strength, pulse duration, number of pulses per a single train of pulses, number of trains per a treatment session and/or interval time between each one of the train of pulses.

17. The method of claims 15 or 16, wherein the parameter comprises a location on the scalp for positioning the magnetic coil.

18. The method of any one of claims 14 to 17, wherein the TMS is selectively delivered to one or more brain regions comprising frontal cortex, insular cortex, prefrontal cortex, dorsolateral prefrontal cortex, Broca, Wernicke, temporal cortex, hippocampi, parietal cortex, cingulate cortex, posterocingulate cortex, occipital cortex, ventrolateral prefrontal cortex, inferior frontal gyrus, sensory cortex, motor cortex, and/or cerebellum.

19. The method of any one of claims 14 to 18, wherein the TMS comprises repetitive TMS with a frequency of 1-9 Hertz.

20. The method of any one of claims 14 to 19, wherein the TMS is delivered to less than 50 % of the brain's volume.

21. The method of any one of claims 3 to 13, further comprising:

administering at least one drug to treat the brain condition.

22. The method of claim 21, further comprising:

changing a dosage and/or administration timing of the drug based on the determining.

23. The method of claims 21 or 22, further comprising:

replacing at least one drug with a different drug for treating the brain condition after the determining.

24. The method of any of the previous claims, wherein the extracting comprises generating at least two topographic microstate maps and/or the occurrence time of each topographic microstate map.

25. A method for generating a risk indication for classifying a subject condition as of one or more clinical conditions based on an EEG signal, comprising: extracting values of one or more microstate parameters from a first EEG signal recorded from the subject; and

calculating a risk indication of one or more clinical conditions based on the extracted one or more microstate parameter values.

26. The method of claim 25, comprising:

analyzing results of one or more cognitive tests performed on the subject, and wherein the calculating comprises calculating a risk indication of the one or more clinical conditions based on the at least one microstate parameter values and the analysis results of the one or more cognitive tests.

27. The method of claims 25 or 26, comprising:

measuring one or more biomarkers in the subject associated with the one or more clinical conditions, and wherein the calculating comprises calculating a risk indication of the one or more clinical conditions based on the at least one microstate parameters values and the measured one or more biomarkers.

28. The method of any one of claims 25 to 27, further comprising:

selecting a treatment to treat the one or more clinical conditions based on the calculated risk indication.

29. The method of any one of claims 25 to 28, further comprising:

modifying one or more parameters of a treatment protocol for the clinical condition based on the risk indication.

30. The method of claim 29, wherein the parameters of a treatment protocol comprise the intensity of the treatment and/or the duration of the treatment protocol and/or the time interval between at least two consecutive treatment sessions of the treatment protocol.

31. The method of any one of claims 25 to 30, wherein the calculating further comprises:

comparing the one or more microstate parameters values to at least one microstates value indication or a range of microstates value indications which represents at least one cognitive and/or clinical condition.

32. The method of any one of claims 25 to 31, comprising:

recording a second EEG signal after a pre-determined time from the first EEG signal; and

wherein the extracting further comprises extracting one or more microstate parameter values from the second EEG signal.

33. The method of claim 32, comprising:

updating the risk indication based on the one or more microstate parameter values of the second EEG signal.

34. The method of claim 33, comprising

determining a progression of the one or more clinical conditions based on the updated risk indication.

35. The method of claim 34, wherein the progression comprises progression from a cognitively normal state to mild cognitive impairment.

36. The method of claim 34, wherein the progression comprises progression from mild cognitive impairment to mild Alzheimer's disease dementia.

37. The method of claim 34, wherein the progression comprises progression from mild Alzheimer's disease dementia to moderate Alzheimer's disease dementia.

38. The method of any one of claims 25 to 37, wherein the clinical conditions comprise Alzheimer's disease, and/or Attention Deficit Hyperactivity Disorder and/or Attention Deficit Disorder and/or Depression and/or vascular dementia and/or mild cognitive impairment and/or normal cognition.

39. The method of any one of claims 25 to 38, wherein the microstate parameters comprise resting state networks or resting state microstate parameters, and wherein the EEG signal is measured when an individual is not actively engaged in sensory and/or cognitive processing.

40. The method of any one of claims 25 to 39, wherein the microstate parameters comprise duration or mean duration of one or more microstates.

41. The method of any one of claims 25 to 40, wherein the microstates parameters comprise occurrence, frequency and/or number of transitions of one or more microstates.

42. A device for calculating a risk indication associated with one or more clinical conditions, comprising:

a memory, wherein the memory stores microstates indications associated with one or more clinical conditions;

a control circuitry connected to at least one EEG electrode and to the memory, wherein the control circuitry extracts values of at least one microstate parameter from an EEG signal, measured by the at least one EEG electrode and calculates a risk indication associated with one or more clinical condition based on the at least one microstates parameters values and the microstates indications stored in the memory.

43. The device of claim 42, wherein the control circuitry selects a treatment protocol adjusted for treating the stage of a clinical condition; and wherein the memory stores the treatment protocol.

44. The device of claims 42 or 43, wherein the control circuitry modifies at least one parameter of a treatment protocol for the treatment of the clinical condition, to adjust the treatment protocol for treating the stage of the clinical condition; and wherein the memory stores the treatment protocol.

45. The device of claims 43 or 44, further comprising a transmitter; wherein the transmitter transmits the treatment protocol for treating the stage of the clinical condition to a magnetic stimulation device.

46. The device of any one of claims 42 to 45, wherein the brain condition comprises Alzheimer's disease or mild cognitive impairment or Attention Deficit Hyperactivity Disorder or Attention Deficit Disorder.

47. The device of any one of claims 42 to 46, wherein the microstate parameters comprise resting state networks, and wherein the EEG signal is measured when an individual is not actively engaged in sensory and/or cognitive processing.

48. The device of any one of claims 42 to 47, wherein the at least one microstate parameter comprises duration or mean duration of one or more microstates.

49. The device of any one of claims 42 to 48, wherein the at least one microstate parameter comprises occurrence, frequency and/or number of transitions of one or more microstates.

50. The device of any one of claims 42 to 49, wherein the memory stores results of a cognitive analysis and/or a psychiatric analysis, and wherein the control circuitry calculates the risk indication based on the values of the at least one

microstates parameter and based on the cognitive analysis results and/or the psychiatric analysis results.